Hepatitis B virus (HBV)-associated nephropathy is one of the manifestations of HBV infection. However, since it is not common, the patient populations of reports are usually limited. In order to have a more perfect understanding of the disease, we conducted this analysis of data published in articles of the English literature on HBV-associated nephropathy. We conducted a comprehensive search for the available publications on HBV-associated nephropathy through the PubMed. The patients were

more »

... d as pediatric when they were 18 years old or younger. The definition criteria for complete remission were in part different between studies, but a generalized definition was taken as a significant decrease in the proteinuria to levels around normal with no relapse episodes in 1 year after remission. Overall, 119 patients from 10 reports were included into this analysis. All of the patients using lamivudine experienced remissions compared to those receiving other treatment modalities (P = .001), of whom 72.7% (16 of 22) had complete remission (P = .08). None of lamivudine recipients lost their kidneys (P = .04). Pediatric patients were more frequently positive for hepatitis B envelop antigen (P = .001). Immunoglobulin A nephropathy was more frequent among adult patients (P = .01), and membranous nephropathy in children (P = .01). Children represented significantly higher levels for aspartate aminotransferase (P = .004) and alanine aminotransferase (P = .002). Lamivudine therapy can effectively be used to stop progression of HBV-associated nephropathy. Pediatric patients represent different serological and laboratorial test results compared to their adult counterparts. Future studies with larger patient population are needed to confirm our findings.